JP5687631B2 - Hcvのマクロ環状プロテアーゼ阻害剤を製造するための方法および中間体 - Google Patents
Hcvのマクロ環状プロテアーゼ阻害剤を製造するための方法および中間体 Download PDFInfo
- Publication number
- JP5687631B2 JP5687631B2 JP2011541509A JP2011541509A JP5687631B2 JP 5687631 B2 JP5687631 B2 JP 5687631B2 JP 2011541509 A JP2011541509 A JP 2011541509A JP 2011541509 A JP2011541509 A JP 2011541509A JP 5687631 B2 JP5687631 B2 JP 5687631B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- solvent
- mixture
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 40
- 239000000543 intermediate Substances 0.000 title description 28
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 79
- 150000001875 compounds Chemical class 0.000 claims description 49
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- -1 bicyclic lactone amide Chemical class 0.000 claims description 47
- KMPWYEUPVWOPIM-KODHJQJWSA-N cinchonidine Chemical class C1=CC=C2C([C@H]([C@H]3[N@]4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-KODHJQJWSA-N 0.000 claims description 47
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 45
- 239000002904 solvent Substances 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 38
- 238000006243 chemical reaction Methods 0.000 claims description 36
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 26
- 239000000725 suspension Substances 0.000 claims description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- 150000003839 salts Chemical group 0.000 claims description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 16
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 claims description 15
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 13
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 7
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 150000002430 hydrocarbons Chemical class 0.000 claims description 6
- 238000001953 recrystallisation Methods 0.000 claims description 6
- 239000004215 Carbon black (E152) Substances 0.000 claims description 5
- 229930195733 hydrocarbon Natural products 0.000 claims description 5
- 239000011877 solvent mixture Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000007822 coupling agent Substances 0.000 claims description 3
- 150000003512 tertiary amines Chemical class 0.000 claims description 3
- 125000005500 uronium group Chemical group 0.000 claims description 3
- 239000008096 xylene Substances 0.000 claims description 3
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 claims description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 2
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 2
- 239000003759 ester based solvent Substances 0.000 claims description 2
- 150000008282 halocarbons Chemical class 0.000 claims description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 2
- 125000000686 lactone group Chemical group 0.000 claims description 2
- QLSTWGZDXAHREY-UHFFFAOYSA-N n-methylhex-1-en-1-amine Chemical compound CCCCC=CNC QLSTWGZDXAHREY-UHFFFAOYSA-N 0.000 claims description 2
- UGLYZKRVGNAOLZ-UHFFFAOYSA-N propan-2-yl 2-propan-2-yloxy-2h-quinoline-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OC(C)C)C(OC(C)C)C=CC2=C1 UGLYZKRVGNAOLZ-UHFFFAOYSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- 239000003245 coal Substances 0.000 claims 1
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 claims 1
- 230000026030 halogenation Effects 0.000 claims 1
- 238000005658 halogenation reaction Methods 0.000 claims 1
- 239000003880 polar aprotic solvent Substances 0.000 claims 1
- PNGLEYLFMHGIQO-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methoxyanilino)-2-hydroxypropane-1-sulfonate;dihydrate Chemical compound O.O.[Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(OC)=C1 PNGLEYLFMHGIQO-UHFFFAOYSA-M 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 23
- 239000011541 reaction mixture Substances 0.000 description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000010410 layer Substances 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 10
- 241000711549 Hepacivirus C Species 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- RWNULKJXVHGAPM-UHFFFAOYSA-N 2-hydroxycyclopentane-1,1-dicarboxylic acid Chemical compound OC1CCCC1(C(O)=O)C(O)=O RWNULKJXVHGAPM-UHFFFAOYSA-N 0.000 description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 150000002148 esters Chemical group 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 150000004322 quinolinols Chemical class 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 238000006751 Mitsunobu reaction Methods 0.000 description 5
- 238000010640 amide synthesis reaction Methods 0.000 description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
- 150000002596 lactones Chemical class 0.000 description 5
- 239000011343 solid material Substances 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229940098779 methanesulfonic acid Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000010948 rhodium Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 3
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005809 transesterification reaction Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 150000003147 proline derivatives Chemical group 0.000 description 2
- 229910052703 rhodium Inorganic materials 0.000 description 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- SAATURWEMJKLCT-UHFFFAOYSA-N 2-oxocyclopentane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCCC1=O SAATURWEMJKLCT-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- JTZZSQYMACOLNN-VDWJNHBNSA-N CC(C)c1c[s]c(-c2cc(O[C@H](C[C@H]3C(N[C@](C4)([C@@H]4/C=C\CCCCN4C)C(NS(C5CC5)(=O)=O)=O)=O)C[C@H]3C4=O)c(ccc(OC)c3C)c3n2)n1 Chemical compound CC(C)c1c[s]c(-c2cc(O[C@H](C[C@H]3C(N[C@](C4)([C@@H]4/C=C\CCCCN4C)C(NS(C5CC5)(=O)=O)=O)=O)C[C@H]3C4=O)c(ccc(OC)c3C)c3n2)n1 JTZZSQYMACOLNN-VDWJNHBNSA-N 0.000 description 1
- LPPRPUJPNUYIKH-UHFFFAOYSA-N CC(C)c1c[s]c(-c2nc(c(C)c(cc3)OC)c3c(O)c2)n1 Chemical compound CC(C)c1c[s]c(-c2nc(c(C)c(cc3)OC)c3c(O)c2)n1 LPPRPUJPNUYIKH-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C)c1c[s]c(-c2nc(c(C)c(cc3)OC)c3c(O[C@@](C[C@]3C(N(C)CCCCC#C)=O)C[C@]3*#C)c2)n1 Chemical compound CC(C)c1c[s]c(-c2nc(c(C)c(cc3)OC)c3c(O[C@@](C[C@]3C(N(C)CCCCC#C)=O)C[C@]3*#C)c2)n1 0.000 description 1
- UPIOQRHKCNFPIL-CDRSNLLMSA-N COC([C@H](C[C@@H](C1)O)[C@@H]1C(O)=O)O Chemical compound COC([C@H](C[C@@H](C1)O)[C@@H]1C(O)=O)O UPIOQRHKCNFPIL-CDRSNLLMSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 101800001020 Non-structural protein 4A Proteins 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000005865 alkene metathesis reaction Methods 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 238000005574 benzylation reaction Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- GMKJWKXCHOWVDN-RNFRBKRXSA-N dimethyl (1r,2r)-4-oxocyclopentane-1,2-dicarboxylate Chemical class COC(=O)[C@@H]1CC(=O)C[C@H]1C(=O)OC GMKJWKXCHOWVDN-RNFRBKRXSA-N 0.000 description 1
- GMKJWKXCHOWVDN-UHFFFAOYSA-N dimethyl 4-oxocyclopentane-1,2-dicarboxylate Chemical compound COC(=O)C1CC(=O)CC1C(=O)OC GMKJWKXCHOWVDN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- NBJXCTLFPNBZSG-HTRCEHHLSA-N ethyl (1r,2s)-1-amino-2-ethenylcyclopropane-1-carboxylate Chemical compound CCOC(=O)[C@@]1(N)C[C@H]1C=C NBJXCTLFPNBZSG-HTRCEHHLSA-N 0.000 description 1
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XDYRBRLMIGIKQW-UHFFFAOYSA-N n-cyclopentylhydroxylamine Chemical compound ONC1CCCC1 XDYRBRLMIGIKQW-UHFFFAOYSA-N 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000003248 quinolines Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000010956 selective crystallization Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- MYXKPFMQWULLOH-UHFFFAOYSA-M tetramethylazanium;hydroxide;pentahydrate Chemical compound O.O.O.O.O.[OH-].C[N+](C)(C)C MYXKPFMQWULLOH-UHFFFAOYSA-M 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/475—Preparation of carboxylic acid esters by splitting of carbon-to-carbon bonds and redistribution, e.g. disproportionation or migration of groups between different molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Furan Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
(a)エーテル形成反応においてチアゾリル置換キノリノール(VII)と式(Xa)のヒドロキシシクロペンチルビス−エステルを反応させて、式(XII)のキノリニルオキシシクロペンチルビス−エステルを得るが、ここで、式(XII)のキノリニルオキシ−シクロペンチルビス−エステルにおいてエーテル基とシス位に向かい合うベンジルエステ
ル基は、選択的にモノカルボン酸(XI)に切断され、これが次に、アミド形成反応においてアルケニルアミンと結合して、式(VI)の所望の最終生成物を得る;あるいは
(b)式(Xa)のヒドロキシシクロペンチルビス−エステルを、選択的にモノカルボン酸(IX)に転化させ、これを次に、アミド形成反応においてアルケニルアミンと結合させて、ヒドロキシシクロペンチルアミド(VIII)を生成し、これを次に、チアゾリル置換キノリノール(VII)と反応させて、式(VI)の所望の最終生成物を得る;
ことによって製造することができる。
治療用途のために許容しうる生成物を得るのに必須である点で特殊な挑戦を提出する。中間体(VI)は3個のキラル中心を有し、そしてすべて3個の中心について正確な立体化学性を得ることは、この化合物を製造することを目的とするいかなる合成方法にとっても重要な挑戦である。したがって、(VI)を製造する方法は、望ましくない立体異性形態の実質的量の喪失とともに、扱い難い精製操作の使用をせずに許容できるキラル純度をもつ生成物を生成することが必要である。
ウム、ヘキサフルオロリン酸ベンゾトリアゾル−1−イル−オキシ−トリス−ピロリジノ−ホスホニウム(PyBOP(R)として市販)、1,1’−カルボニルジイミダゾール(CDI)、1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミド(EDIまたはEDCI)ならびにその塩酸塩、ジシクロヘキシル−カルボジイミド(DCC)または1,3−ジイソプロピルカルボジイミド、ヘキサフルオロリン酸O−ベンゾトリアゾール−N,N,N’,N’−テトラメチル−ウロニウム(HBTU)などを含む。触媒、例えば、1−ヒドロキシベンゾトリアゾール(HOBt)または4−ジメチルアミノピリジン(DMAP)が添加されてもよい。反応は、通常、塩基、特に第3級アミンのようなアミン塩基、例えばトリエチルアミン、N−メチルモルホリン、N,N−ジイソプロピルエチルアミン、(後者はまたHuenig塩基、DIPEAまたはDIEAと呼ばれる)の存在下で実施される。好ましくは、塩基は使用されない。1つの実施態様では、反応は、反応混合液の還流温度において、場合によっては反応の末期にメタノールを添加して、EEDQを用いてDCMまたはMeTHF中で実施される。
− ステレオボンドなしに表される化合物、例えば化合物(XV)はラセミ体であるか、または立体形成中心の配置が定義されない。
− ステレオボンドおよび記述子「(±)」、「rel」、または「rac」の1つにより表される化合物はラセミ体であり、そして立体化学性は相対的である。
− ステレオボンドをもつが記述子「(±)」、「rel」、または「rac」なしに表される化合物は非ラセミ化合物(scalemic substance)またはenantio−enrichedを指す、すなわち立体化学性は絶対的である。
容量の80%を30mbarの圧力下で溜去した。反応フラスコを2−メチル−テトラヒドロフランを満たされるDean−Starkトラップに固定した。2−メチルテトラヒドロフラン(100ml)を反応フラスコに添加し、これを4時間還流して残存する水を除去した。溶媒容量の80%を周囲圧力下で溜去した。混合液を50℃まで冷却し、そしてアセトン(380ml)を添加した。混合液をさらに22℃まで冷却し、再びアセトン(760ml)を添加した。得られる懸濁液を窒素雰囲気下で−5℃まで冷却し、そしてトリエチルアミン(27.8ml,20.24g,0.2mol)を添加した。次いで、クロロギ酸エチル(22.68g,0.21mol)を滴下し、混合液を0℃で3時間撹拌した。反応混合液を22℃に加温し、さらに12時間撹拌し、次いで、dicalite上で濾過し、そして固形物をアセトン(100ml)で洗浄した。アセトン中(XV)の得られる溶液を次の実施例で使用して、そのシンコニジン塩を製造した。
溶媒容量の約80%を大気圧下で溜去した。酢酸エチル(190ml)を添加し、そして有機溶液をHCl水溶液(2M,114ml)で洗浄して、酢酸エチル中(XV)の溶液を得た。酢酸エチル中(XV)の溶液を60℃においてアセトニトリル(760ml)中シンコニジン(55.94g,0.19mol)の懸濁液に添加した。得られる混合液を60℃で10分間撹拌し、次いで22℃まで冷却し、濾過した。固体をイソプロパノール(1500ml)から再晶出させて、乾燥後白色固体の24.8g(収率29%)を得た。キラル純度:e.r.:89/11
溶媒容量の約80%を大気圧下で溜去した。酢酸エチル(522ml)を添加し、そして溶媒容量の約50%を溜去した。残液を22℃まで冷却し、酢酸エチル(180ml)を添加した。得られる懸濁液を濾過し、そして濾液をアセトニトリル(760ml)中シンコニジン(55.94g,0.19mol)の懸濁液に添加した。この混合液を60℃まで加温し、10分間撹拌し、次いで22℃まで冷却し、濾過した。固体をイソプロパノール(1500ml)から再晶出させて、乾燥後白色固体の24.8g(収率29%)を得た。キラル純度:e.r.:90/10
方法2の操作に従うが、アセトニトリル(760ml)中シンコニジン(55.94g,0.19mol)の懸濁液を、イソプロパノール(325ml)とエタノール(325ml)中シンコニジン(55.94g,0.19mol)の懸濁液に変更して、白色固体の24.8g(29%)を得た。キラル純度:e.r.:92/8
(a)粗(XVIa)2.00gをアセトン10.4ml中に懸濁し、その懸濁液を還流させ、その後室温まで冷却させた。固形物を濾過し、アセトンで洗浄し、真空下50℃で乾燥して、白色粉末として純(XVIa)210mgを得た。収率:35%。
、この懸濁液を2日間還流した。トルエン22mlを添加し、そして溶媒28mlを溜去した。50−60℃に冷却後、1NHCl水溶液19.4mlを添加し、2層を分離した。有機層を水5.6mlで洗浄し、次いで、真空濃縮し、その残渣をフラッシュクロマトグラフィーによって精製して、(XVIII)910mgを得た。収率:65%。
13C NMR(CDCl3,150MHz,2種の回転異性体の存在):多量の回転異性体:ppm 25.86,26.39,33.24,33.94,35.17,37.43,37.97,45.71,47.95,80.67,114.71,138.26,170.91,177.33−少量の回転異性体:ppm 25.7,27.72,33.14,33.69,34.29,36.72,38.02,46.19,49.61,80.64,115.22,137.73,171.17,177.28.
に懸濁した。この混合液を24時間還流し、次いで。トルエン178mlを添加した。溶媒250mlを溜去し、得られる懸濁液を30℃に冷却した。1MHCl水溶液155mlを添加し、2層を分離した。水層をトルエン44mlで2回抽出した。合わせた有機層を硫酸マグネシウムで乾燥し、濾過して、トルエン中4.1wt/wt%(VIIIa)溶液の122.78gを得た。収率:40%。
し、そして溶媒25mlを溜去した。残留物を80℃まで冷却し、イソプロパノール25mlおよびdicalite415mgを添加し,懸濁液を還流し、そして熱時濾過した。濾液を30℃まで冷却し、そして(VIa)2.4mgを種晶として添加した。懸濁液を0℃まで冷却し、この温度で一夜撹拌した。(VIa)を濾過し、冷イソプロパンール2.5mlで洗浄し、そして真空乾燥して、白色粉末24.3gを得た。収率:80%。
Claims (29)
- R1がメチルである、請求項1の方法。
- アミド形成反応が、反応に不活性な溶媒中、アミドカップリング剤の存在下で実施される、請求項1または2の方法。
- 反応が、塩基の存在下で実施される、請求項3の方法。
- 溶媒が、ハロゲン化炭化水素、エーテル、アルコール、炭化水素溶媒、双極性非プロトン性溶媒、またはそれらの混合液を含む、請求項3または4の方法。
- ハロゲン化炭化水素がジクロロメタン(DCM)またはクロロホルム、エーテルがテトラヒドロフラン(THF)または2−メチルテトラヒドロフラン(MeTHF)、アルコールがメタノールまたはエタノール、炭化水素溶媒がトルエンまたはキシレン、双極性非プロトン性溶媒がDMF、DMA、アセトニトリルである、請求項5の方法。
- アミド形成剤が、N−エトキシカルボニル−2−エトキシ−1,2−ジヒドロキノリン(EEDQ)、N−イソプロポキシカルボニル−2−イソプロポキシ−1,2−ジヒドロキノリン(IIDQ)、ヘキサフルオロリン酸N,N,N’,N’−テトラメチル−O−(7−アザベンゾトリアゾル−1−イル)ウロニウム、ヘキサフルオロリン酸ベンゾトリアゾル−1−イル−オキシ−トリス−ピロリジノ−ホスホニウム、CDI、1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミド(EDCI)またはその塩酸塩、ジシクロヘキシル−カルボジイミド(DCC)、1,3−ジイソプロピルカルボジイミド、またはヘキサフルオロリン酸O−ベンゾトリアゾール−N,N,N’,N’−テトラメチル−ウロニウム(HBTU)の剤を含む、請求項3または4の方法。
- アミド形成剤が、触媒の存在下にある、請求項7の方法。
- 触媒が、1−ヒドロキシベンゾトリアゾール(HOBt)または4−ジメチルアミノピリジン(DMAP)である、請求項8の方法。
- 塩基が、第3級アミンである、請求項4の方法。
- 第3級アミンが、トリエチルアミン、N−メチルモルホリン、N,N−ジイソプロピルエチルアミンである、請求項10の方法。
- シンコニジンの懸濁液が50から70℃の温度において(XV)の溶液に添加され、続いて混合液を冷却させ、それによって所望の生成物(XXa)が晶出する、請求項13の方法。
- (XV)がエステル溶媒から選ばれる溶媒中に溶解され、そしてシンコニジン懸濁液のための溶媒がアセトニトリルを含む、請求項13の方法。
- エステル溶媒が酢酸エチルである、請求項15の方法。
- 塩形成が60℃の温度で実施され、そして混合液が室温まで冷却される、請求項14または15の方法。
- 混合液が20〜25℃の範囲の温度まで冷却される、請求項17の方法。
- 塩が適当な溶媒または溶媒混合液からの再結晶化によるか;あるいは溶媒または溶媒混合液中に再スラリー化することによってさらに精製される、請求項14または15の方法。
- 再結晶化における溶媒が、C1-4アルカノールであるか、または再スラリー化において溶媒または溶媒混合液がエタノール/水混合液である、請求項19の方法。
- C 1-4 アルカノールがイソプロパノールであり、および/または、エタノール/水混合液が5%/95%(w/w)水/エタノール混合液である、請求項20の方法。
- 中間体(VIII)の製造における中間体としての、請求項22に定義されたシンコニジン塩(XXa)の使用。
- 請求項24記載の、式(I)の化合物を製造する方法であって、請求項12〜21のいずれか1に記載の式(XXa)の化合物を製造する方法に続いて、式(I)の化合物に変換することを含んでなる、上記方法。
- 請求項1〜11のいずれかに記載の方法に従って、式(XXa)の化合物が最初に式(VIII)の化合物に変換される、請求項26に記載の方法。
- 式(VIII)の化合物から式(I)の化合物への変換が請求項25記載の通りである、請求項27に記載の方法。
- (I)が請求項24に定義された通りである式(I)の化合物の製造における中間体としての、請求項22に定義された通りであるシノコニジン塩(XXa)の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08172691.1 | 2008-12-23 | ||
| EP08172691 | 2008-12-23 | ||
| PCT/EP2009/067715 WO2010072742A1 (en) | 2008-12-23 | 2009-12-22 | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012513381A JP2012513381A (ja) | 2012-06-14 |
| JP2012513381A5 JP2012513381A5 (ja) | 2013-10-24 |
| JP5687631B2 true JP5687631B2 (ja) | 2015-03-18 |
Family
ID=40548041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011541509A Expired - Fee Related JP5687631B2 (ja) | 2008-12-23 | 2009-12-22 | Hcvのマクロ環状プロテアーゼ阻害剤を製造するための方法および中間体 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8927722B2 (ja) |
| EP (1) | EP2382198B1 (ja) |
| JP (1) | JP5687631B2 (ja) |
| KR (1) | KR101734507B1 (ja) |
| CN (1) | CN102264715B (ja) |
| AR (1) | AR074863A1 (ja) |
| AU (1) | AU2009331530B2 (ja) |
| BR (1) | BRPI0923393B1 (ja) |
| CA (1) | CA2745565C (ja) |
| CY (1) | CY1114488T1 (ja) |
| DK (1) | DK2382198T3 (ja) |
| ES (1) | ES2429013T3 (ja) |
| HR (1) | HRP20130906T1 (ja) |
| IL (1) | IL213246A (ja) |
| MX (1) | MX2011006764A (ja) |
| PL (1) | PL2382198T3 (ja) |
| PT (1) | PT2382198E (ja) |
| RU (1) | RU2016120007A (ja) |
| SI (1) | SI2382198T1 (ja) |
| SM (1) | SMT201300116B (ja) |
| TW (1) | TWI461424B (ja) |
| WO (1) | WO2010072742A1 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2382198T3 (pl) | 2008-12-23 | 2013-11-29 | Janssen Pharmaceuticals Inc | Sposoby i półprodukty do otrzymywania makrocyklicznego inhibitora proteazy HCV |
| WO2013041655A1 (en) | 2011-09-22 | 2013-03-28 | Janssen Pharmaceuticals, Inc. | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
| KR20140086967A (ko) * | 2011-10-28 | 2014-07-08 | 얀센 파마슈티칼즈, 인코포레이티드 | 거대고리 프로테아제 저해제 tmc435의 중간체를 제조하는 개선된 방법 |
| CN103387509B (zh) * | 2012-05-11 | 2016-06-08 | 重庆博腾制药科技股份有限公司 | 一种hcv蛋白酶抑制剂中间体的制备方法 |
| NZ724616A (en) * | 2012-06-08 | 2018-06-29 | Gilead Sciences Inc | Macrocyclic inhibitors of flaviviridae viruses |
| AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| WO2013185103A1 (en) * | 2012-06-08 | 2013-12-12 | Gilead Sciences, Inc. | Macrocyclic inhibitors of flaviviridae viruses |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| US9617310B2 (en) | 2013-03-15 | 2017-04-11 | Gilead Sciences, Inc. | Inhibitors of hepatitis C virus |
| WO2015180253A1 (zh) * | 2014-05-29 | 2015-12-03 | 杭州普晒医药科技有限公司 | 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途 |
| MA41812A (fr) | 2015-03-27 | 2018-01-30 | Janssen Pharmaceuticals Inc | Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8300536A (nl) | 1983-02-14 | 1984-09-03 | Oce Andeno Bv | Optisch actief alfa-azido-p-hydroxyfenylazijnzuur en zijn zouten alsmede de bereiding daarvan. |
| JPS6124539A (ja) * | 1984-07-11 | 1986-02-03 | Sagami Chem Res Center | 光学活性(r)−2,5,12−トリヒドロキシ−1,2,3,4−テトラヒドロナフタセン−6,11−ジオン−2−カルボン酸の取得方法 |
| JP4218040B2 (ja) * | 1997-12-26 | 2009-02-04 | 曽田香料株式会社 | 有機酸とアミンの複合塩の製造法 |
| JP3844112B2 (ja) | 2000-08-23 | 2006-11-08 | 高砂香料工業株式会社 | 3,5,6−トリヒドロキシヘキサン酸アンモニウム塩誘導体、及びその製造方法 |
| EP1713822B1 (en) * | 2004-01-30 | 2010-03-17 | Medivir AB | Hcv ns-3 serine protease inhibitors |
| CN101146794A (zh) | 2005-01-21 | 2008-03-19 | 阿斯泰克斯治疗有限公司 | 用于抑制cdk和gsk的吡唑衍生物 |
| PE20070211A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| CN101273030B (zh) * | 2005-07-29 | 2012-07-18 | 泰博特克药品有限公司 | 丙型肝炎病毒的大环抑制剂 |
| KR101598135B1 (ko) * | 2007-02-01 | 2016-02-26 | 얀센 사이언시즈 아일랜드 유씨 | Hcv의 마크로사이클릭 프로테아제 억제제의 제조 방법 및 중간체 |
| ES2432590T3 (es) * | 2007-02-08 | 2013-12-04 | Janssen R&D Ireland | Fenilcarbamatos macrocíclicos inhibidores del VHC |
| PL2382198T3 (pl) | 2008-12-23 | 2013-11-29 | Janssen Pharmaceuticals Inc | Sposoby i półprodukty do otrzymywania makrocyklicznego inhibitora proteazy HCV |
-
2009
- 2009-12-22 PL PL09801447T patent/PL2382198T3/pl unknown
- 2009-12-22 HR HRP20130906AT patent/HRP20130906T1/hr unknown
- 2009-12-22 AR ARP090105059 patent/AR074863A1/es unknown
- 2009-12-22 DK DK09801447.5T patent/DK2382198T3/da active
- 2009-12-22 US US13/141,715 patent/US8927722B2/en not_active Expired - Fee Related
- 2009-12-22 CA CA2745565A patent/CA2745565C/en not_active Expired - Fee Related
- 2009-12-22 MX MX2011006764A patent/MX2011006764A/es active IP Right Grant
- 2009-12-22 AU AU2009331530A patent/AU2009331530B2/en not_active Ceased
- 2009-12-22 BR BRPI0923393-8A patent/BRPI0923393B1/pt not_active IP Right Cessation
- 2009-12-22 JP JP2011541509A patent/JP5687631B2/ja not_active Expired - Fee Related
- 2009-12-22 TW TW98144049A patent/TWI461424B/zh not_active IP Right Cessation
- 2009-12-22 SI SI200930731T patent/SI2382198T1/sl unknown
- 2009-12-22 WO PCT/EP2009/067715 patent/WO2010072742A1/en not_active Ceased
- 2009-12-22 EP EP09801447.5A patent/EP2382198B1/en active Active
- 2009-12-22 ES ES09801447T patent/ES2429013T3/es active Active
- 2009-12-22 RU RU2016120007A patent/RU2016120007A/ru not_active Application Discontinuation
- 2009-12-22 CN CN200980152851.5A patent/CN102264715B/zh not_active Expired - Fee Related
- 2009-12-22 PT PT09801447T patent/PT2382198E/pt unknown
- 2009-12-22 KR KR1020117017333A patent/KR101734507B1/ko not_active Expired - Fee Related
-
2011
- 2011-05-31 IL IL213246A patent/IL213246A/en not_active IP Right Cessation
-
2013
- 2013-10-10 SM SM201300116T patent/SMT201300116B/xx unknown
- 2013-10-10 CY CY20131100890T patent/CY1114488T1/el unknown
-
2014
- 2014-11-25 US US14/552,550 patent/US9115077B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5687631B2 (ja) | Hcvのマクロ環状プロテアーゼ阻害剤を製造するための方法および中間体 | |
| KR101598135B1 (ko) | Hcv의 마크로사이클릭 프로테아제 억제제의 제조 방법 및 중간체 | |
| RU2588132C2 (ru) | Способы и промежуточные соединения для получения макроциклического ингибитора протеазы вируса гепатита с | |
| JP6235473B2 (ja) | 大環状hcvプロテアーゼ阻害剤を製造するための方法および中間体 | |
| HK1164839B (en) | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv | |
| HK1137442B (en) | Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130904 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20131205 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140114 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140414 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140421 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140514 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140521 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140613 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140620 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140709 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141224 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150122 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5687631 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |